BSEM (BioStem Technologies) Cyclically Adjusted Revenue per Share: $ (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSEM BioStem Technologies Inc BSEM
37 GF Score
Price $4.40
! 6 Warning Signs
View Full Analysis

What is BioStem Technologies Cyclically Adjusted Revenue per Share?

BioStem Technologies BSEM -6.88% 37 Cyclically Adjusted Revenue per Share is $ as of Jun. 2026. GuruFocus rates BSEM with a GF Score™ of 37/100. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BioStem Technologies's adjusted revenue per share for the three months ended in Jun. 2026 was $0.456. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $ for the trailing ten years ended in Jun. 2026.

During the past 12 months, BioStem Technologies's average Cyclically Adjusted Revenue Growth Rate was 54.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 102.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -46.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of BioStem Technologies was 102.70% per year. The lowest was -76.50% per year. And the median was -65.50% per year.

As of today (2026-09-22), BioStem Technologies's current stock price is $4.40. BioStem Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $. BioStem Technologies's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioStem Technologies was 58.46. The lowest was 0.05. And the median was 5.71.


BioStem Technologies  (NAS:BSEM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of BioStem Technologies was 58.46. The lowest was 0.05. And the median was 5.71.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BioStem Technologies Cyclically Adjusted Revenue per Share Related Terms


BioStem Technologies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies Cyclically Adjusted Revenue per Share Chart

BioStem Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioStem Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BSEM vs IBIO, CSBR, PLRX: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, BioStem Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioStem Technologies Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioStem Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioStem Technologies's Cyclically Adjusted PS Ratio falls into.


BSEM
37GF Score
BioStem Technologies Inc BSEM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioStem Technologies's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.456/333.9520*333.9520
=0.456

Current CPI (Jun. 2026) = 333.9520.

BioStem Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 0.127 238.132 0.178
201606 0.068 241.018 0.094
201609 0.068 241.428 0.094
201612 0.067 241.432 0.093
201703 0.037 243.801 0.051
201706 0.026 244.955 0.035
201709 0.010 246.819 0.014
201712 0.008 246.524 0.011
201803 0.009 249.554 0.012
201806 0.005 251.989 0.007
201809 0.046 252.439 0.061
201812 0.059 251.233 0.078
201903 0.058 254.202 0.076
201906 0.077 256.143 0.100
202003 0.085 258.115 0.110
202006 0.026 257.797 0.034
202009 0.052 260.280 0.067
202012 0.103 260.474 0.132
202103 0.096 264.877 0.121
202106 0.100 271.696 0.123
202109 0.129 274.310 0.157
202112 0.127 278.802 0.152
202203 0.291 287.504 0.338
202206 0.185 296.311 0.209
202209 0.098 296.808 0.110
202212 0.065 296.797 0.073
202303 0.046 301.836 0.051
202306 0.081 305.109 0.089
202309 0.259 307.789 0.281
202312 0.769 306.746 0.837
202403 2.168 312.332 2.318
202406 3.561 314.175 3.785
202409 0.871 315.301 0.923
202412 0.992 315.605 1.050
202503 0.608 319.799 0.635
202506 0.468 322.561 0.485
202509 0.451 324.800 0.464
202512 0.600 324.054 0.618
202603 0.364 330.213 0.368
202606 0.456 333.952 0.456

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $ mean?
BioStem Technologies (BSEM) has a Cyclically Adjusted Revenue per Share of $ as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioStem Technologies and its competitors.
Is BioStem Technologies' Cyclically Adjusted Revenue per Share too high?
BioStem Technologies' current Cyclically Adjusted Revenue per Share is $. Overall, BioStem Technologies has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' Cyclically Adjusted Revenue per Share compare to IBIO and CSBR?
BioStem Technologies' Cyclically Adjusted Revenue per Share of $ can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current Cyclically Adjusted Revenue per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
BioStem Technologies (BSEM) has a current Cyclically Adjusted Revenue per Share of $. The current Cyclically Adjusted Revenue per Share is $. BioStem Technologies' overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current Cyclically Adjusted Revenue per Share is $ as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioStem Technologies Business Description

Other Exchanges 0JQ:Germany
Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
37GF Score

Get the complete analysis for BSEM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.40
Price